Novel PET biomarkers for breast cancer imaging

Nuclear Medicine Communications

Volumn 32, Issue 5, 2011, Pages 333-335

  Kenny, Laura M ^a   Al Nahhas, Adil ^b   Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CHOLINE; ESTRADIOL; FLUOROESTRADIOL; KI 67 ANTIGEN; METHIONINE; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; HUMAN; IMAGE ANALYSIS; MOLECULAR IMAGING; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

BREAST NEOPLASMS; DIDEOXYNUCLEOSIDES; ESTRADIOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; METHIONINE; POSITRON-EMISSION TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 79955041164     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834471ff     Document Type: Review

References (35)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
2. Ellis PA, Makris A, Burton SA, Titley J, Ormerod MG, Salter J, et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 1996; 73:640-643. (Pubitemid 26068870)
3. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32 825 patients. Breast 2008; 17:323-334.
4. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99:167-170.
5. Silvestrini R, Daidone MG, Luisi A, Mastore M, Leutner M, Salvadori B. Cell proliferation in 3800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer 1997; 74:122-127. (Pubitemid 27157866)
6. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-5165.
7. Meyer JS, Wittliff JL Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int J Cancer 1991; 47:213-220.
8. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11:2785-2808. (Pubitemid 40525178)
9. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009; 115:5038-5047.
10. Kenny LM, Aboagye EO, Price PM. Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol) 2004; 16:176-185. (Pubitemid 38559685)
11. 11C]thymidine PET imaging studies: validation studies. J Nucl Med 1999; 40:614-624. (Pubitemid 29171803)
12. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLTwith thymidine. Nucl Med Biol 2005; 32:663-671. (Pubitemid 41502970)
13. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 3'-deoxy-3'-[(18)F]fluorothymidine into L51 78Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2004; 32:257-263. (Pubitemid 40562116)
14. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336. (Pubitemid 28512118)
15. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006; 66:8558-8564. (Pubitemid 44449169)
16. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991; 266:9032-9038. (Pubitemid 21906614)
17. Plotnik DA, Emerick LE, Krohn KA, Unadkat JD, Schwartz JL. Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med 2010; 51:1464-1471.
18. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005; 65:10104-10112. (Pubitemid 41541493)
19. Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, et al. Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol 55:695-709.
20. Van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45:695-700. (Pubitemid 47618601)
21. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34:1339-1347. (Pubitemid 47312585)
22. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8:36-42. (Pubitemid 44201576)
23. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005; 32:15-22. (Pubitemid 40142774)
24. 18F-fluoroestradiol. J Nucl Med 2008; 49:367-374. (Pubitemid 351355201)
25. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006; 24:2793-2799. (Pubitemid 46630578)
26. Breillout F, Antoine E, Poupon MF. Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 1990; 82:1628-1632. (Pubitemid 20345300)
27. Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991; 64:1121-1124.
28. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 1993; 67:787-791. (Pubitemid 23101560)
29. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer a method for early therapy evaluation? J Clin Oncol 1995; 13:1470-1477.
30. Inoue T, Kim E, Wong F, Yang D, Bassa P, Wong W, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 1996; 37:1472-1476. (Pubitemid 26321625)
31. Lindholm P, Lapela M, Nagren K, Lehikoinen P, Minn H, Jyrkkio S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009; 30:30-36.
32. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59:80-84. (Pubitemid 29062961)
33. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodŕiguez- González A, Olmeda D, Megías D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004; 64:6732-6739. (Pubitemid 39297936)
34. 11C]Choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009; 15:5503-5510.
35. 11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 2010; 16:4236-4245.